Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Filings indexed 581 across all filing types
Latest filing 2026-04-10 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
8-K - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Filer)
Regulatory Filings
2026-04-10 English
144 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Subject)
Regulatory Filings
2026-03-27 English
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
Director's Dealing
2026-03-17 English
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
Director's Dealing
2026-03-17 English
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
Director's Dealing
2026-03-17 English
4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)
Director's Dealing
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.